Mahalakshmi Radhakrishnan
Director/Board Member presso ALTO NEUROSCIENCE, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Mahalakshmi Radhakrishnan occupa la posizione di Chief Medical Officer & Group Senior VP presso Biogen, Inc. La dott.ssa Radhakrishnan è anche Senior Vice President & Head-Worldwide Medical presso Bioverativ Therapeutics, Inc. Nella sua carriera passata la dott.ssa Radhakrishnan ha ricoperto la posizione di Vice Presidente per Biogen, Inc, Global Head-Medical & Primary Care Business Unit presso Sanofi e Executive Director & Head-Therapeutic Area presso Bristol-Myers Squibb Holdings Pharma LLC. Mahalakshmi Radhakrishnan ha ricevuto un dottorato dalla Peoples' Friendship University della Russia.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ALTO NEUROSCIENCE, INC.
-.--% | 08/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Mahalakshmi Radhakrishnan
Società | Posizione | Inizio |
---|---|---|
ALTO NEUROSCIENCE, INC. | Director/Board Member | 08/03/2024 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Director/Board Member | 29/11/2022 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Director/Board Member | 05/01/2023 |
Precedenti posizioni note di Mahalakshmi Radhakrishnan
Società | Posizione | Fine |
---|---|---|
BIOGEN INC. | Chief Tech/Sci/R&D Officer | 01/03/2024 |
SANOFI | Corporate Officer/Principal | 01/01/2019 |
BIOASIS TECHNOLOGIES INC. | Director/Board Member | 27/07/2018 |
BIOGEN INC. | Corporate Officer/Principal | 01/10/2016 |
Bristol-Myers Squibb Holdings Pharma LLC
Bristol-Myers Squibb Holdings Pharma LLC Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Pharma Ltd. engages in the pharmaceutical company. The company is headquartered in San Juan, Puerto Rico. | Director/Board Member | 01/04/2013 |
Formazione di Mahalakshmi Radhakrishnan
Peoples' Friendship University of Russia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
BIOGEN INC. | Health Technology |
SANOFI | Health Technology |
BIOASIS TECHNOLOGIES INC. | Health Technology |
Aziende private | 5 |
---|---|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Health Technology |
Bristol-Myers Squibb Holdings Pharma LLC
Bristol-Myers Squibb Holdings Pharma LLC Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Pharma Ltd. engages in the pharmaceutical company. The company is headquartered in San Juan, Puerto Rico. | Health Technology |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Commercial Services |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Health Technology |
Alto Neuroscience, Inc. |
- Borsa valori
- Insiders
- Mahalakshmi Radhakrishnan